Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hiroyuki Shimaoka"'
Autor:
Hiroyuki Shimaoka, Naoki Kohira, Hidenori Yoshizawa, Yuki Murakami, Hitoshi Murai, Masayuki Sano
Publikováno v:
Chemistry Letters. 49:1497-1500
Third-generation cephalosporins possess broad spectrum and potent activities against Gram-positive and Gram-negative bacteria. In order to establish a general methodology for improving the oral bio...
Autor:
Naoki Kohira, Hiroyuki Shimaoka, Hidenori Yoshizawa, Masayuki Sano, Hitoshi Murai, Yuki Murakami
Publikováno v:
Chemistry Letters. 49:1501-1503
Macrocyclization can help improve pharmacological activity, metabolic stability, cell permeability and oral absorption to create better drug candidates. For example, enhancing the oral absorption o...
Publikováno v:
The Proceedings of the Symposium on Micro-Nano Science and Technology. :20am2PN313
Autor:
Yumiko Matsuo, Seijiro Hara, Takushi Kanazu, Hiroyuki Shimaoka, Kenji Miyata, Hiroyuki Kusuhara, Shingo Sakamoto, Noboru Okamura, Takahiko Baba, Kazutoshi Horie, Yuichi Sugiyama, Kohji Nomura
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 322:610-618
Methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) is a novel inhibitor of the ileal apical sodium-dependent bile acid transporter (ASBT/SLC10A2) developed for the treatment of hypercholesterolemia. The
Publikováno v:
Pharmaceutical Research. 23:1729-1735
Prodrugs with pivalic acid and valproic acid decrease L-carnitine concentration in plasma and tissues by urinary excretion of acylcarnitine as pivaloylcarnitine (PC) and valproylcarnitine (VC), respectively. We investigated the role of the Na+/L-carn
Publikováno v:
Pharmaceutical Research; Aug2006, Vol. 23 Issue 8, p1729-1735, 7p